Literature DB >> 20395330

Time course of Paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer.

Paola A Erba1, Chiara Manfredi, Elena Lazzeri, Fabrizio Minichilli, Ernest K J Pauwels, Alberto Sbrana, H William Strauss, Giuliano Mariani.   

Abstract

UNLABELLED: Early assessment of the efficacy of treatment is important in patients with breast cancer, whose routine adjuvant regimen frequently includes chemotherapy. Irrespective of the exact mechanisms involved in induction, the common early phenotypic marker of apoptosis is the expression on the outer cell membrane surface of phosphatidylserine, which avidly binds annexin V. (99m)Tc-labeled annexin V has been proposed for in vivo scintigraphic detection of apoptosis, albeit with contradicting results. This study was performed to define the time course of apoptosis induced by the chemotherapeutic agent paclitaxel in a model of virus-induced murine breast cancer.
METHODS: The RIII virus induces an estrogen-dependent, slow-growing breast cancer; BALB-c/cRIII female mice with breast tumors averaging 10 mm were studied, both in baseline conditions and at various times after the intravenous administration of paclitaxel (equivalent to a human dose of 20 mg/70 kg of body weight). The biodistribution of (99m)Tc-annexin V was evaluated at baseline and then at 1, 3, 6, and 24 h after paclitaxel administration. Apoptotic and antiapoptotic markers were also evaluated in tumor samples obtained at the same time points: DNA breaks (terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling [TUNEL]), active caspase-3, apoptosis-inducing factor, and Bcl-2 protein.
RESULTS: Baseline uptake of (99m)Tc-annexin V in breast tumors was about 2-fold higher than the uptake in normal breast tissue (demonstrating some ongoing apoptosis); tracer uptake increased at 1 and 3 h after paclitaxel administration (to almost double the baseline value) and then declined to levels even lower than baseline. Although no activation of the apoptosis-inducing factor mechanism was detected, a peak in TUNEL-positive tumor cells was reached 3 h after paclitaxel administration (to more than 6-fold the baseline level). The antiapoptotic marker Bcl-2 exhibited a biphasic pattern, with a maximum drop at 3 h, followed by return toward baseline levels at 6 h.
CONCLUSION: These results define the time course of various biologic events taking place in this model of murine breast cancer after a proapoptotic insult (single-dose paclitaxel). Although confirming that in vivo uptake of (99m)Tc-annexin V reflects the degree of apoptosis, the study also suggests that the apoptotic response to antitumor therapy may differ from tumor type to tumor type. Therefore, contradicting results previously reported may depend on an inadequate time window chosen for imaging with (99m)Tc-annexin V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395330     DOI: 10.2967/jnumed.109.071621

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

Review 1.  (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.

Authors:  Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-16       Impact factor: 9.236

2.  Cancer Cell-targeted and Activatable Photoimmunotherapy Spares T Cells in a 3D Coculture Model.

Authors:  Eric M Kercher; Shubhankar Nath; Imran Rizvi; Bryan Q Spring
Journal:  Photochem Photobiol       Date:  2019-10-13       Impact factor: 3.421

3.  Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy.

Authors:  S Dizdarevic; R McCready; J F C Turner; M C Bagley; P Blower; P Schmid; G Flux; A Hall; I Ziv
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

4.  Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.

Authors:  Paul R Lockman; Rajendar K Mittapalli; Kunal S Taskar; Vinay Rudraraju; Brunilde Gril; Kaci A Bohn; Chris E Adkins; Amanda Roberts; Helen R Thorsheim; Julie A Gaasch; Suyun Huang; Diane Palmieri; Patricia S Steeg; Quentin R Smith
Journal:  Clin Cancer Res       Date:  2010-09-09       Impact factor: 12.531

5.  Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death.

Authors:  Seth T Gammon; Brian J Engel; Gregory J Gores; Erik Cressman; David Piwnica-Worms; Steven W Millward
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

Review 6.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

7.  Longitudinal bioluminescence imaging of the dynamics of Doxorubicin induced apoptosis.

Authors:  Gang Niu; Lei Zhu; Don N Ho; Fan Zhang; Haokao Gao; Qimeng Quan; Naoki Hida; Takeaki Ozawa; Gang Liu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2013-02-21       Impact factor: 11.556

8.  Circadian Influences on Chemotherapy Efficacy in a Mouse Model of Brain Metastases of Breast Cancer.

Authors:  William H Walker; Samuel A Sprowls; Jacob R Bumgarner; Jennifer A Liu; O Hecmarie Meléndez-Fernández; James C Walton; Paul R Lockman; A Courtney DeVries; Randy J Nelson
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.